CAESAREA, Israel--(BUSINESS WIRE)--
Mazor Robotics Ltd. (TASE:MZOR; NASDAQCM:MZOR), (the “Company”) the
developer of Renaissance™, an innovative surgical guidance system and
its complementary products, announced today the pricing of its public
offering of 2,400,000 American Depositary Shares (“ADSs”) at a price of
$17.00 per ADS. The gross proceeds to the Company from the offering are
expected to be $40,800,000 before underwriting discounts and commissions
and other offering expenses. All of the ADSs in the offering are being
offered by the Company. In addition, the Company has granted the
underwriters a 30-day option to purchase up to 360,000 additional ADSs
at the offering price. The offering is expected to close on November 4,
2013, subject to customary closing conditions.
Barclays Capital Inc. is acting as sole book-running manager with
Ladenburg Thalmann & Co. Inc., JMP Securities LLC and First Analysis
Securities Corporation acting as co-managers of the offering.
A registration statement relating to these securities has been filed
with, and declared effective by, the Securities and Exchange Commission.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
The offering is being made only by means of a prospectus, copies of
which may be obtained, when available, from Barclays Capital Inc., c/o
Broadridge Financial Solutions, 1155 Long Island Ave., Edgewood, New
York 11717, or by email at [email protected],
or by calling (888) 603-5847.
About Mazor
Mazor Robotics (TASE:MZOR; NASDAQCM:MZOR) is dedicated to the
development and marketing of innovative surgical robots and
complementary products that provide a safer surgical environment for
patients, surgeons, and operating room staff. Mazor Robotics' flagship
product, Renaissance™, is a state-of-the-art surgical guidance system
that enables surgeons to conduct spine surgeries in an accurate and
secure manner. Mazor Robotics systems have been successfully used in the
placement of over 35,000 implants in the United States and Europe.
Numerous peer-reviewed publications and presentations at leading
scientific conferences have validated the accuracy, usability, and
clinical advantages of Mazor Robotics technology.
Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any
statements in this release about future expectations, plans or prospects
for the Company, including without limitation, statements regarding our
public offering and its anticipated closing date, and other statements
containing the words “believes,” “anticipates,” “plans,” “expects,”
“will” and similar expressions are forward-looking statements. These
statements are only predictions based on Mazor's current expectations
and projections about future events. The forward-looking statements
contained or implied in this press release are subject to risks and
uncertainties, including those discussed under the heading "Risk
Factors" in Mazor's registration statement on Form F-1 filed with the
Securities and Exchange Commission ("SEC") and in subsequent filings
with the SEC. For more details, refer to Mazor's SEC filings and the
amendments thereto, including its Registration Statement on Form 20-F
filed on May 10, 2013 and its Current Reports on Form 6-K. Mazor
undertakes no obligation to update forward-looking statements to reflect
subsequent occurring events or circumstances, or to changes in our
expectations, except as may be required by law.
